Format

Send to:

Choose Destination
See comment in PubMed Commons below
Virology. 2000 May 10;270(2):254-7.

Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.

Author information

  • 1Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892-4040, USA. roden@jhmi.edu

Abstract

Vaccination with virus-like particles (VLP), comprising both L1 and L2 of human papillomavirus (HPV) genital types 6, 16, and 18, induces predominantly type-specific neutralizing antibodies. L2 polypeptide vaccines protect animals against experimental challenge with homologous papillomavirus and cross-reactive epitopes are present in HPV L2. To assess L2-specific cross-neutralization of HPV genotypes, sheep were immunized with purified, bacterially expressed HPV6, 16, or 18 L2. In addition to neutralizing the homologous HPV type in vitro, antisera to each HPV L2 also cross-neutralized both heterologous HPV types. This suggests that unlike VLP-based prophylactic HPV vaccines, an L2 polypeptide vaccine may provide broad-spectrum protection.

Copyright 2000 Academic Press.

PMID:
10792983
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk